Grünenthal is a global leader in pain management. Our purpose is to change lives for the better – and innovation is our passion. We are driven to seek effective, life-changing medicines and solutions for patients with severe diseases and high unmet medical needs.

... Company

A world free of pain. This is our shared vision. To bring it to life, we execute our strategy and work on our company’s culture – everyday, everywhere, every one of us.

... We are Grünenthal

Although firmly rooted in Germany, today we are very much a growing global Business.

... History

A mix of strong entrepreneurial spirit, close collaboration and outstanding performance define our approach to leadership alongside a commitment to diversity and inclusivity.

... Leadership

The Supervisory Board advises and controls the Corporate Executive Board and is elected by the shareholders’ summit.

... Supervisory Board

In view of our vision of a World Free of Pain, Grünenthal strives to provide effective medication to patients worldwide. Therefore, we continuously grow and expand our market presence and product portfolio, and we collaborate with commercial partners and multiple stakeholders from the pain management field and beyond.

... Global presence & sites

Grünenthal’s product portfolio, brands, ingredients and indication range.

... Products

Explore our media section and access a range of materials relating to our company, people, medicines and medical devices.

... Media

Grünenthal is a global leader in pain management and related diseases. Our purpose is to change lives for the better – and innovation is our passion. We are focusing all of our activities and efforts on moving towards our vision of a world free of pain. Explore our recent stories to see what drives us.

... Our Stories

In this section you will find both current and archived press releases published from 2013 onwards by Grünenthal GmbH, Germany.

... Press releases

... Statements

Journalists are invited to use our corporate publications for their reporting. The list contains business related publication like the company presentation or the code of conduct. .

... Corporate publications

Journalists are invited to use images from our library to illustrate their reporting. The library contains company and R&D related pictures.

... Image resources

The library contains a set of company footage. Journalists are invited to use the video material to illustrate their reporting.

... Video resources

A World Free of Pain

Out now: Virtual company showcase

Grünenthal is a global leader in pain management.

Grünenthal is a global leader in pain management and related diseases. As a science-based, privately-owned pharmaceutical company, we have a long track record of bringing innovative treatments and state-of-the-art technologies to patients worldwide. Our purpose is to change lives for the better, and innovation is our passion. We are focusing all our activities and efforts on working towards our vision of a world free of pain.

Katrin Fleischer, Global Regulatory Strategy

Sabine Hess, Technician Cellular & Molecular Biology

Andrew Lockhart, Head Translational and Disease Understanding Unit

Grünenthal Stories

View All

100 Reasons for a World Free of Pain - Sandra Ventura & Vasco Lobo

Relieving chronic pain is the focus of our daily work – and it affects many Grünenthal employees in their personal lives too. In this short interview, Sandra Ventura and Vasco Lobo explain how personal experiences of chronic pain inspire their professional life.

04 December 2024

MSCI awards Provisional AA score in ESG rating 

Grünenthal is taking action to maximise its contribution to people’s lives and minimise its environmental impact. An external assessment from MSCI recognises our industry-leading approach to these topics by awarding our company a Provisional AA rating.

21 November 2024

Diabetes and pain: a focus on polyneuropathy on World Diabetes Day

Today is World Diabetes Day, which reminds us of the widespread nature of diabetes and the health challenges that those affected must overcome.

14 November 2024

20 countries certified Great Place to Work®

Record-high results and more entities certified in 2024 Great Place to Work® survey

More than 3,700 Grünenthal employees gave feedback during the global Great Place to Work® survey in 2024. 83% of them consider Grünenthal a great place to work. In addition, 20 of our operating countries were certified as a Great Place to Work.

18 October 2024

Karen’s story: Living with osteoarthritis of the knees

Our Grünenthal colleague Karen shares her experience of living with osteoarthritis in her knee.

12 October 2024

Group of smiling warehouse workers at our production site in Chile

Our holistic approach to health

Every day, 4,400 employees worldwide drive Grünenthal forward. They can only make that impact if they are safe and healthy. How is Grünenthal ensuring wellbeing for its global team? We asked Director Global Environment, Health & Safety, Fuad Mahmood.

01 October 2024

Phase III trial AV001 with QUTENZA®: Recruitment completed

Qutenza^® Phase III trial AV001: Recruitment completed

Grünentha's U.S. subsidiary, Averitas Pharma, Inc., has completed recruitment for the Phase III clinical trial AV001. The trial investigates the efficacy, safety and tolerability of QUTENZA^® (capsaicin) 8% topical system in post-surgical neuropathic pain (PSNP) and if successful could support an extension of the U.S. label.

Read the press release on the AV001 trial recruitment completion

NOP First-In-Human-Trial Announcement Grünenthal

First participants enrolled in Phase I NOP trial

Grünenthal announced that the first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist. The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and tolerability profile and to confirm the pharmacokinetic characteristics of the compound after single and multiple ascending doses. The results of the trial are expected in Q3 2025.

Get more insides in our press release

Annual Report 2023/24

4,400 Grünenthal employees worldwide join forces every day to drive progress towards our vision of a World Free of Pain. Together, we achieved record revenues in 2023. And our scientists made important progress with developing innovative medicines for pain patients.

Our most recent report shares information about our company’s strategy, highlight projects and financial performance.

Check out the Grünenthal Report.

Responsibility Report 2023

Grünenthal’s strategy and culture are closely tied to its deep commitment to conducting business responsibly. We aim to have a net-positive impact on patients, employees, partners, and wider society. Each year, we publish our progress in a detailed and externally audited report – in line with the Global Reporting Initiative (GRI) standards.

Check out our latest Responsibility Report.